Erythroblastaemia in natalizumab-treated patients with multiple sclerosis
详细信息 查看全文
- 作者：Sara La Gioiaa ; saralagioia@yahoo.it" class="auth_mail" title="E-mail the corresponding author ; Michela Seghezzib ; mikymik89@gmail.com" class="auth_mail" title="E-mail the corresponding author ; Valeria Barcellaa ; valeria.barcella@gmail.com" class="auth_mail" title="E-mail the corresponding author ; Paola Dominonib ; pdominoni@hpg23.it" class="auth_mail" title="E-mail the corresponding author ; Tommaso Meccab ; tommalloredus@hotmail.it" class="auth_mail" title="E-mail the corresponding author ; Barbara Frigenia ; barbarafrigeni@hotmail.com" class="auth_mail" title="E-mail the corresponding author ; Marta Zaffira Contia ; martazaffira@virgilio.it" class="auth_mail" title="E-mail the corresponding author ; Marcella Vedovelloa ; marcellavedovello@gmail.com" class="auth_mail" title="E-mail the corresponding author ; Matteo Vidalic ; matteo.vidali@med.uniupo.it" class="auth_mail" title="E-mail the corresponding author ; Mariarosa Rottolia ; mrottoli@hpg23.it" class="auth_mail" title="E-mail the corresponding author ; Sabrina Buorob ; sbuoro@hpg23.it" class="auth_mail" title="E-mail the corresponding author
- 关键词：Multiple sclerosis ; Natalizumab ; Erythroblasts
- 刊名：Multiple Sclerosis and Related Disorders
- 出版年：2016
- 出版时间：July 2016
- 年：2016
- 卷：8
- 期：Complete
- 页码：141-144
- 全文大小：286 K
文摘
- •
Early papers on the use of natalizumab in RRMS patients reported erythroblastemia as occasional.
- •
Our data show that erythroblastaemia is more frequent on natalizumab than other treatments.
- •
The clinical significance is unknown.